Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Lymphohistiocytosis, Hemophagocytic 2Myelodysplastic Syndromes 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1Cytopenia 1Bone Marrow Failure Disorders 1Anemia, Aplastic 1

Interventions

fludarabine phosphate 7fludarabine 6Cyclophosphamide 5Whole-Body Irradiation 4Busulfan 4Antilymphocyte Serum 4Alemtuzumab 3Thiotepa 2Tacrolimus 2Peripheral Blood Stem Cell Transplantation 2Mycophenolic Acid 2Melphalan 2Clofarabine 2treosulfan 1thymoglobulin 1posaconazole 1eltrombopag 1X-Rays 1Therapeutics 1Specimen Handling 1Sirolimus 1Passive Cutaneous Anaphylaxis 1Morphine 1Methylprednisolone Hemisuccinate 1Methylprednisolone 1Methotrexate 1Methadone 1Hydromorphone 1Genetic Counseling 1Erythrocyte Transfusion 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Bone Marrow Failure Disorders × Emapalumab × Clear all
NCT06430788 2025-12-17

A Study of Emapalumab for Pediatric Aplastic Anemia

Memorial Sloan Kettering Cancer Center

Phase 2 Recruiting
35 enrolled
Classical hematology

Bone Marrow Failure Disorders, Cytopenia, Anemia, Aplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡